BioNTech
BNTX

$118.80

5.09%

Market Cap: $28.2B

About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Employees: 6,133

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 15 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

6% more call options, than puts

Call options by funds: $145M | Put options by funds: $137M

0% less funds holding

Funds holding: 283 [Q1] → 282 (-1) [Q2]

0.44% less ownership

Funds ownership: 17.67% [Q1] → 17.24% (-0.44%) [Q2]

3% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 37

14% less repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 98

15% less capital invested

Capital invested by funds: $3.88B [Q1] → $3.29B (-$587M) [Q2]

See Fund Rankings

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$85

28%

downside

Avg. target

$119

0%

upside

High target

$150

26%

upside

15 analyst ratings

10 positive

67%

4 neutral

27%

1 negative

7%

Morgan Stanley Terence Flynn 85% 1-year accuracy 17 / 20 met price target	22%upside $145	Overweight Upgraded	24 Sept 2024
Deutsche Bank Emmanuel Papadakis 50% 1-year accuracy 1 / 2 met price target	26%upside $150	Buy Maintained	19 Sept 2024
UBS Eliana Merle 42% 1-year accuracy 5 / 12 met price target	10%upside $131	Neutral Maintained	18 Sept 2024
Jefferies Akash Tewari 33% 1-year accuracy 5 / 15 met price target	26%upside $150	Buy Upgraded	17 Sept 2024
JP Morgan Jessica Fye 66% 1-year accuracy 25 / 38 met price target	5%upside $125	Neutral Upgraded	16 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about BNTX published over the past 30 days

Zacks Investment Research

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission wil.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024 Doses will be ready to ship to applicable European Union member states as soon as possible upon European Commission authorization NEW YORK and MAINZ, GERMANY, SEPTEMBER 20, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission (“EC”) will review the CHMP's recommendation and is expected to make a final decision soon.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.

Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.

BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.

Investors Business Daily

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech's “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech's and InstaDeep's AI strategy and capabilities, and the application of AI in BioNTech's pipeline and internal processes.

BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024

CNBC Television

Trade It or Fade It: The week's big biotech moves

Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.

Trade It or Fade It: The week's big biotech moves

Zacks Investment Research

BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?

BioNTech's Low Valuation, Many Shots On Goal Make It A Buy

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivonescimab. Despite declining Covid-19 vaccine revenue and safety concerns about those shot, BioNTech's low valuation and promising pipeline make it a buy for risk-tolerant, long-term investors.

BioNTech's Low Valuation, Many Shots On Goal Make It A Buy

BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches.

BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

See News Rankings